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Abstract: The antinociceptive effects produced by intraperitoneal administration of a novel synthetic
chalcone, 3-(2,3-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (DMFP), were investigated
in several mouse models of induced nociception. The administration of DMFP (0.1, 0.5, 1.0 and
5.0 mg/kg) produced significant attenuation on the acetic acid-induced abdominal-writhing test.
It also produced a significant increase in response latency time in the hot-plate test and a marked
reduction in time spent licking the injected paw in both phases of the formalin-induced paw-licking
test. In addition, it was also demonstrated that DMFP exhibited significant inhibition of the
neurogenic nociceptive response induced by intraplantar injections of capsaicin and glutamate.
Moreover, the antinociceptive effect of DMFP in the acetic acid-induced abdominal-writhing test
and the hot-plate test was not antagonized by pretreatment with a non-selective opioid receptor
antagonist, naloxone. Finally, DMFP did not show any toxic effects and/or mortality in a study of
acute toxicity and did not interfere with motor coordination during the Rota-rod test. Our present
results show that DMFP exhibits both peripheral and central antinociceptive effects. It was suggested
that its peripheral antinociceptive activity is associated with attenuated production and/or release
of NO and various pro-inflammatory mediators, while central antinociceptive activity seems to
be unrelated to the opioidergic system, but could involve, at least in part, an interaction with the
inhibition of capsaicin-sensitive fibers and the glutamatergic system.
Keywords: 3-(2,3-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one; chalcone; antinociceptive
activity; opioidergic system; TRPV1 receptor; glutamatergic system
1. Introduction
Pain remains a major issue in a vast array of medical conditions. Although many effective
and potent pharmacotherapies such as opioids and non-steroidal anti-inflammatory analgesic drugs
are available, they all have limitations. The continuous use of these analgesic drugs is generally
followed by undesirable adverse side effects, such as gastrointestinal damage, renal toxicity, tolerance
and respiratory depression [1–3]. Therefore, the search for new analgesic compounds with good
efficacy and least undesirable side effects to alleviate this obstinate painful condition is potentially very
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important and is now an interesting strategy. Taking these into consideration, compounds showing an
analgesic effect have appeared as attractive therapeutic sources for the development of new relevant
drugs for the management of several painful conditions.
Chalcones (1,3-diaryl-2-propen-1-ones) represent an important group of natural or synthetic
compounds belonging to the flavonoid family. They have been reported to exhibit broad spectrum
of biological and pharmacological activities, such as antimicrobial [4], anticancer [5], antiulcer [6],
antinociceptive [7–9], anti-inflammatory [10], among others, and thus comprise a class with important
therapeutic potential. Many chalcones and their synthetic derivative analogues have been found
to inhibit the synthesis of nitric oxide (NO) and prostaglandins (PG), which are products of the
nitric oxide synthase (NOS) and cyclooxygenase (COX) pathways, respectively. These pathways
constitute the major proinflammatory pathways and remain the most targeted for anti-inflammatory
and antinociceptive drugs development [11–14].
Our ongoing interest in the search for novel analgesic agents has led to the investigation of
naturally occurring chemical resources [15–18] as well as synthetic analogues based on natural
products [9,19]. Recently, we have investigated that chalcones bearing substituted furanyl group,
3-(2,3-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (DMFP, Figure 1) showed remarkable
anti-inflammatory activity. It was demonstrated that this compound significantly and potently
suppressed NO in interferon-c (IFN-c)- and lipopolysaccharide (LPS)-activated RAW 264.7 cells [20].
In light of the significant activity of DMFP in the attenuation of NO-related effects, which have
also been associated with the development of pain, this compound was further synthesized in our
laboratory and evaluated with respect to its antinociceptive properties. We herein report the findings
on the antinociceptive activity of DMFP using several in vivo experimental models of chemicals- and
heat-induced nociception in mice and elucidate some of its possible mechanisms of action.
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Figure 1. Chemical structure of 3-(2,3-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (DMFP). 
2. Results 
2.1. Antinociceptive Studies 
2.1.1. Acetic Acid-Induced Writhing Test 
The effect of DMFP on writhing response in mice is shown in Figure 2, DMFP (0.1, 0.5, 1.0, and 
5.0 mg/kg, i.p.) administered intraperitoneally (i.p.) caused dose-dependent inhibition on the writhing 
response induced by acetic acid with 13.89% (p < 0.01), 32.41% (p < 0.001), 59.95% (p < 0.001) and 
91.14% (p < 0.001) of inhibition as compared to control, respectively. Such effect was also observed in 
mice pre-treated by ASA with 44.25% (p < 0.05) inhibition. The calculated mean ID50 for i.p. administered 
DMFP in this model was 0.85 mg/kg (CI, 0.76 to 0.95 mg/kg). 
2.1.2. Formalin-Induced Paw-Licking Test 
As shown in Figure 3, the i.p. treatment with DMFP at the doses of 0.1, 0.5,1.0 and 5.0 mg/kg 
significantly inhibited the licking time in of both neurogenic (0–5 min, panel A), by 18.85% (p < 0.5), 
31.41% (p < 0.001), 41.88% (p < 0.001) and 68.41% (p < 0.001), and inflammatory (15-30 min, panel B), by 
19.60% (p < 0.01), 43.10% (p < 0.001), 65.07% (p < 0.001) and 80.04% (p < 0.001), phases of formalin-induced 
paw-licking test, when compared to control group. The treatment with ASA (100 mg/kg, i.p.) only 
significantly inhibited the licking time in inflammatory phase by 18.96% (p < 0.01). On contrary, 
morphine (5 mg/kg, i.p.) significantly inhibited both phases of the test by 51.49% and 69.00% (p < 0.001), 
respectively. 
Figure 1. Chemical structure of 3-(2,3-dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (DMFP).
2. Results
2.1. Antinociceptive Studies
2.1.1. Acetic Acid-Induced Writhing Test
The effect of DMFP on writhing response in mice is shown in Figure 2, DMFP (0.1, 0.5, 1.0, and
5.0 mg/kg, i.p.) administered intraperitoneally ( .p.) caused dose- epe dent inhibit on on the writhing
response induced by acetic acid with 13.89% (p < 0.01), 32.41% (p < 0.001), 59.95% (p < 0.001) and 91.14%
(p < 0.001) of inhibition as compared to control, respectively. Such effect was also observed in mice
pre-treated by ASA with 44.25% (p < 0.05) inhibition. The calculated mean ID50 for i.p. administered
DMFP in thi model was 0.85 mg/kg (CI, 0.76 to 0.95 mg/kg).
2.1.2. Formalin-Induced Paw-Licking Test
As shown in Figure 3, the i.p. treat ent with DMFP at the doses of 0.1, 0.5,1.0 and 5.0 mg/kg
significantly inhibited the licking time in of both neurogenic (0–5 min, panel A), by 18.85% (p < 0.5),
31.41% (p < 0.001), 41.88% (p < 0.001) and 68.41% (p < 0.001), and inflammatory (15-30 min, panel B),
by 19.60% (p < 0.01), 43.10% (p < 0.001), 65.07% (p < 0.001) and 80.04% (p < 0.001), phases of
formalin-induced paw-licking test, when compared to control group. The treatment with ASA
(100 mg/kg, i.p.) only significantly inhibited the licking time in inflammatory phase by 18.96%
(p < 0.01). On contrary, morphine (5 mg/kg, i.p.) significantly inhibited both phases of the test by
51.49% and 69.00% (p < 0.001), respectively.
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Figure 2. Effect of DMFP (0.1, 0.5, 1 and 5 mg/kg, i.p.) in acetic acid-induced abdominal-writhing test 
in mice. Each column represents the mean ± S.E.M. (n = 6). The mice were pretreated with vehicle  
(C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 1.0 and 5.0 mg/kg, i.p.) or acetylsalicylic acid (ASA, 100 mg/kg, 
i.p.). The asterisks denote significance levels ** p < 0.01, *** p < 0.001, when compared with the control 
vehicle group. Statistical significance was determined by one-way ANOVA followed by Dunnett’s 
post-hoc test. Values in parentheses are percentages of inhibition. 
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Figure 3. Effect of DMFP in formalin-induced paw-licking test (early phase, panel (A); and late phase, 
panel (B) in mice. Each column represents the mean ± S.E.M. (n = 6). The mice were pretreated with 
vehicle C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 1.0 and 5.0 mg/kg, i.p.), acetylsalicylic acid (ASA, 100 mg/kg, 
i.p.) or morphine (MOR, 5 mg/kg, i.p.). The asterisks denote the significance levels * p < 0.5, ** p < 0.01, 
*** p < 0.001, when compared with control vehicle group. Statistical significance was determined by 
one-way ANOVA followed by Dunnett’s post-hoc test. Values in parentheses are percentage of inhibition. 
2.1.3. Hot-Plate Test 
As depicted in Figure 4, DMFP treatment at doses of 1.0 and 5.0 mg/kg significantly increased 
the response latency to a heat stimulus 30 min after the treatment and persisted until 180 min in 
comparison to the control group (vehicle 10 mL/kg). 
DMFP at doses of 0.1 and 0.5 mg/kg significantly increased response latency time at 150 min after 
the treatment in comparison to the control. The positive control group, morphine (5 mg/kg, i.p.), 
increased the response latency to heat stimulation 30 min after administration. This effect was 
maintained until 180 min after the treatment (p < 0.001). 
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Figure 3. Effect of DMFP in formalin-induced paw-licking test (early phase, panel (A); and late phase, 
panel (B) in mice. Each column represents the mean ± S.E.M. (n = 6). The mice were pretreated with 
vehicle C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 1.0 and 5.0 mg/kg, i.p.), acetylsalicylic acid (ASA, 100 mg/kg, 
i.p.) or morphine (MOR, 5 mg/kg, i.p.). The asterisks denote the significance levels * p < 0.5, ** p < 0.01, 
*** p < 0.001, when compared with control vehicle group. Statistical significance was determined by 
one-way ANOVA followed by Dunnett’s post-hoc test. Values in parentheses are percentage of inhibition. 
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As depicted in Figure 4, DMFP treatment at doses of 1.0 and 5.0 mg/kg significantly increased 
the response latency to a heat stimulus 30 min after the treatment and persisted until 180 min in 
comparison to the control group (vehicle 10 mL/kg). 
DMFP at doses of 0.1 and 0.5 mg/kg significantly increased response latency time at 150 min after 
the treatment in comparison to the control. The positive control group, morphine (5 mg/kg, i.p.), 
increased the response latency to heat stimulation 30 min after administration. This effect was 
maintained until 180 min after the treatment (p < 0.001). 
Figure 3. Effect of DMFP in formalin-induced paw-licking test (early phase, panel (A); and late
phase, panel (B) in mice. Each column represents the mean ± S.E.M. (n = 6). The mice were
pretreated with vehicle C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 1.0 and 5.0 mg/kg, i.p.), acetylsalicylic acid
(ASA, 100 mg/kg, i.p.) or morphine (MOR, 5 mg/kg, i.p.). The asterisks denote the significance levels
* p < 0.5, ** p < 0.01, *** p < 0.001, when compared with control vehicle group. Statistical significance
was determined by one-way ANOVA followed by Dunnett’s post-hoc test. Values in parentheses are
percentage of inhibition.
2.1.3. Hot-Plate Test
As depicted in Figure 4, DMFP treatment at doses of 1.0 and 5.0 mg/kg significantly increased
the response latency to a heat stimulus 30 min after the treatment and persisted until 180 min in
comparison to the control group (vehicle 10 mL/kg).
DMFP at doses of 0.1 and 0.5 mg/kg significantly increased response latency time at 150 min
after the treatment in comparison to the control. The positive control group, morphine (5 mg/kg, i.p.),
increased the response latency to heat stimulation 30 min after administration. This effect was
maintained until 180 min after the treatment (p < 0.001).
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Figure 4. Effect of DMFP on the hot plate test in mice. Results are expressed in mean ± S.E.M. of 
response latency (s) of 6 mice. Statistical significance was denoted by one-way ANOVA followed by 
Dunnett’s post-hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with control group; Control ( ), 
DMFP ( , 0.1; , 0.5;  1.0;  5.0 mg/kg, i.p.). 
2.1.4. Capsaicin-Induced Paw-Licking Test 
The administration of DMFP produced significant dose-dependent inhibition of the capsaicin- 
induced neurogenic nociception at all doses, as compared to control group with a highest activity of 
79.91% (p < 0.001) observed at the dose of 5.0 mg/kg (Figure 5). A similar inhibitory effect was also 
observed for capsazepine, which achieved 69.44% (p < 0.001) inhibition of capsaicin-induced nociception. 
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Figure 5. Effect of DMFP against capsaicin-induced paw-licking test in mice. Each column represents 
the mean ± S.E.M. of 6 mice. The mice were pre-treated with vehicle (C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 
1.0 and 5 mg/kg, i.p.) or capsazepine (CAP, 0.17 mmol, i.p.) 30 min before intraplantar (i.pl.) injection of 
capsaicin (1.6 μg/paw, 20 μL). The asterisks denote the significance levels * p < 0.05, *** p < 0.001, 
when compared with control group (one-way ANOVA followed by Dunnett’s post-hoc test). Values 
in parentheses are percentage of inhibition. 
2.1.5. Glutamate-Induced Paw-Licking Test 
The results presented in Figure 6 show that the i.p. administration of DMFP at doses of 0.1, 0.5, 
1.0 and 5.0 mg/kg caused significant dose-dependent inhibition of glutamate-induced nociception, 
with 21.74% (p < 0.001), 40.67% (p < 0.001), 59.45% (p < 0.001) and 81.51% (p < 0.001) of inhibition as 
compared to control, respectively. 
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response latency (s) of 6 mice. Statistical significance was denoted by one-way ANOVA followed by 
Dun ett’s post-hoc test. * p < 0. 5; ** p < 0. 1; **  p < 0. 01 compared with control group; Control ( ), 
DMFP (  , 0.1;  , 0.5;  1.0;  5.0 g/kg, i. .). 
2.1.4. Capsaic n-Induced Paw-Licking Test 
The administration of DMFP produced significant dose-dependent inhibit on of the capsaic n- 
induced neurogenic noci eption at all doses, as compared to control group with a highest activity of 
79.91% (p < 0.0 1) observed at he dose of 5.0 mg/kg (Figure 5). A similar inhibitory effect was also 
observed for capsazepine, which achieved 69.4 % (p < 0.0 1) inhibit on of capsaic n-induced noci eption. 
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Figure 5. Effect of DMFP against capsaic n-induced paw-licking test in mice. Each column represents 
the mean ± S.E.M. of 6 mice. The mice wer  pre-treated with vehicle (C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 
1.0 and 5 mg/kg, i.p.) or capsazepine (CAP, 0.17 m ol, i.p.) 30 min before intraplantar (i.pl.) injection of 
capsaic n (1.6 μg/paw, 20 μL). The asterisks denote the signif cance levels * p < 0. 5, **  p < 0. 01, 
when compared with control group (one-way ANOVA followed by Dun ett’s post-hoc test). Values 
in parentheses are percentage of inhibit on. 
2.1.5. Glutamate-Induced Paw-Licking Test 
The results presented in Figure 6 show that he i.p. administration of DMFP at doses of 0.1, 0.5, 
1.0 and 5.0 mg/kg caused signif cant dose-dependent inhibit on of glutamate-induced noci eption, 
with 21.74% (p < 0.0 1), 40.67% (p < 0.0 1), 59.45% (p < 0.0 1) and 81.51% (p < 0.0 1) of inhibit on as 
compared to control, respectively. 
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2.1.4. Capsaicin-I duced Paw-Lick ng Test 
The administra ion f DMFP produced significant dose-d p ndent i hibit on f the capsaicin- 
induced neurogenic nociception at ll doses, a compared to c ntrol group with a hig est activity of
79.91% (p < 0.0 1) observ d at he dose of 5.0 mg/k  (Figure 5). A sim lar inhibitory eff ct was lso 
observ d for caps zepine, whic  achiev d 69.4 % (p < 0.0 1) inh bit on f caps icin- duced nociception. 
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Figure 5. Effect of DMFP against caps icin- duced paw-lick ng tes  in mice. Each olumn rep sents 
the m an ± S.E.M  of 6 mice. The mice w re pre-t at d with vehicle (C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 
1.0 and 5 mg/k , i.p.) or caps zepine (CAP, 0.17 m ol, i.p.) 30 min before intrapl nt r (i.pl ) injection f
caps icin (1.6 μg/paw, 20 μL). The asterisks denote he signif can e levels * p < 0.05, *** p < 0. 1, 
when compared with control group (one-way ANOVA foll wed by Dun ett’s post-hoc tes ). Values 
in parentheses are p rc ntage of inhibit on. 
2.1.5. Glutam te-Induced Paw-Lick ng Test 
The r sults pres nt d in Figure 6 show tha  he i.p. administra ion f DMFP at doses of 0.1, 0.5, 
1.0 and 5.0 mg/k  caused significant dose-d p ndent inhibit on f glutam te-induced nociception, 
with 21.74% (p < 0.0 1), 40.67% (p < 0.0 1), 59.45% (p < 0.0 1) and 81.5 % (p < 0.0 1) of inhibit on as
compared to c ntrol, respectively. 
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induced neurogenic oci eption at al dose , a  compared to c ntrol group with a ig est ac iv y of 
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C 0.1 0.5 1 5 CAP
0
20
40
60
80
100
Li
ck
in
g 
tim
e 
(s
) *
*
*
*
(10. 6)
(31.54)
(4 .50) (36.40)
*
(79.91)
DMFP (mg/kg, i.p.)  
Figure 5. Ef ect of DMFP ag inst caps icin-induced paw-licking test in mice. Each column rep es nt  
the m an ± S.E.M. of 6 mice. The mice w r  p -t ea ed with ve icle (C, 10 mL/kg, i.p.), DMFP (0.1, 5
1.0 and 5 mg/k , i.p.) or caps zepin  (CAP, 0.17 m ol, i.p.) 30 min befor  intraplantar (i.pl.) injection of 
caps icin (1.6 μg/paw, 20 μL). The asteri k  denot  th  sign fican e lev ls * p < 0.05, * p < 0.001, 
when compared with contr l group (one-way ANOVA fol owed by Dunnet ’s po t-hoc test). Values 
in parenth s  are percentage of inh bit on. 
2.1.5  Glutam te-Induced Paw-Lick ng Test 
The result  pres nt d in Figure 6 show tha  the i.p  admin stration f DMFP at dose  of 0.1, .5, 
1.0 and 5.0 mg/k  caused sign ficant dose-d pend t i h b t on f glutam te-induced noci eption, 
with 21.74% (p < 0. 1), 40.67% (p < 0. 1), 59.4 % (p < 0. 1) and 81.5 % (p < 0. 1) of inh b t on as 
compared to c ntrol, esp ctively. 
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e ad inistration of DMFP pro uced sig ificant dos - pe dent i hibition of the
capsaicin-induced neurog nic ocicepti n at ll dos s, as c mpared to control group with highest
activity of 79 91% (p < 0.001) observed at the dose of 5.0 mg/kg (Figure 5). A similar inhibit ry
ffect was also obs rved for capsazepine, which ac ieved 69.44% (p < 0.001) inhibiti f
capsaicin-induced nociception.
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Figure 4. Effect of DMFP on the hot plate test in mice. Results are expressed in mean ± S.E.M. of 
response latency (s) of 6 mice. Statistical significance was denoted by one-way ANOVA followed by 
Dunnett’s post-hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with control group; Control ( ), 
DMFP ( , 0.1; , 0.5;  1.0;  5.0 mg/kg, i.p.). 
2.1.4. Capsaicin-Induced Paw-Licking Test 
The administration of DMFP produced significant dose-dependent inhibition of the capsaicin- 
induced neurogenic nociception at all doses, as compared to control group with a highest activity of 
79.91% (p < 0.001) observed at the dose of 5.0 mg/kg (Figure 5). A similar inhibitory effect was also 
observed for capsazepine, which achieved 69.44% (p < 0.001) inhibition of capsaicin-induced nociception. 
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Figure 5. Effect of DMFP against capsaicin-induced paw-licking test in mice. Each column represents 
the mean ± S.E.M. of 6 mice. The mice were pre-treated with vehicle (C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 
1.0 and 5 mg/kg, i.p.) or capsazepine (CAP, 0.17 mmol, i.p.) 30 min before intraplantar (i.pl.) injection of 
capsaicin (1.6 μg/paw, 20 μL). The asterisks denote the significance levels * p < 0.05, *** p < 0.001, 
when compared with control group (one-way ANOVA followed by Dunnett’s post-hoc test). Values 
in parentheses are percentage of inhibition. 
2.1.5. Glutamate-Induced Paw-Licking Test 
The results presented in Figure 6 show that the i.p. administration of DMFP at doses of 0.1, 0.5, 
1.0 and 5.0 mg/kg caused significant dose-dependent inhibition of glutamate-induced nociception, 
with 21.74% (p < 0.001), 40.67% (p < 0.001), 59.45% (p < 0.001) and 81.51% (p < 0.001) of inhibition as 
compared to control, respectively. 
Figure 5. Effect of DMFP against capsaicin-induced paw-licking test in mice. Each column represents
the mean± S.E.M. of 6 mice. The mice were pre-treated with vehicle (C, 10 mL/kg, i.p.), DMFP (0.1, 0.5,
1.0 and 5 mg/kg, i.p.) or capsazepine (CAP, 0.17 mmol, i.p.) 30 min before intraplantar (i.pl.) injection
of capsaicin (1.6 µg/paw, 20 µL). The asterisks denote the significance levels * p < 0.05, *** p < 0.001,
when compared with control group (one-way ANOVA followed by Dunnett’s post-hoc test). Values in
parentheses are percentage of inhibition.
2.1.5. Glutamate-Induced Paw-Licking Test
The results presented in Figure 6 show that the i.p. administration of DMFP at doses of 0.1, 0.5,
1.0 and 5.0 mg/kg caused significant dose-dependent inhibition of glutamate-induced nociception,
Molecules 2016, 21, 1077 5 of 16
with 21.74% (p < 0.001), 40.67% (p < 0.001), 59.45% (p < 0.001) and 81.51% (p < 0.001) of inhibition as
compared to control, respectively.
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Figure 6. Effect of DMFP against glutamate-induced paw-licking test in mice. Each column represents 
the mean ± S.E.M. of 6 mice. The mice were pre-treated with vehicle (C), or DMFP (0.1, 0.5, 1 and  
5 mg/kg, i.p.) 30 min before i.pl. injection of 20 μL of glutamate (10 μmol/paw). The asterisks denote 
the significance level *** p < 0.001, when compared with control group (one-way ANOVA followed 
by Dunnett’s post-hoc test). Values in parentheses are percentage of inhibition. 
2.1.6. Involvement of Opioid Receptor 
The pre-administration of non-selective opioid receptor antagonist naloxone (5 mg/kg, i.p.) 
significantly antagonized the antinociceptive effect of morphine (5 mg/kg, i.p.) but was not able to 
antagonized the antinociceptive effect of DMFP (1 mg/kg, i.p.) in both the acetic acid-induced 
abdominal-writhing test (Figure 7) and the hot-plate test (Figure 8). Administration of naloxone per 
se did not affect both tests. 
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Figure 7. Effect of treatment with opioid antagonist, naloxone on the acetic acid-induced abdominal- 
writhing test in mice. Mice were pre-treated with naloxone (NALX, 5 mg/kg, i.p.) 15 min before the 
treatment with vehicle (C, 10 mL/kg, i.p), DMFP (0.1, 0.5, 1.0, 5.0 mg/kg, i.p.), or morphine (MOR,  
5 mg/kg, i.p.). Each column represents the mean ± S.E.M. of six mice. The asterisks denote significance 
levels *** p < 0.001, when compared with vehicle control group; ### p < 0.001, when compared with 
morphine (MOR)-treated group; ns denotes no significance level when compared with DMFP-treated 
group (one-way ANOVA followed by Dunnett’s post-hoc test.) 
t
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to antagonized the antinociceptive effect of DMFP (1 mg/kg, i.p.) in both the acetic aci -i ce
ab o i al- rit i g test (Figure 7) and the hot-plate test (Figure 8). Administration of naloxone per se
did not affect both tests.
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Figure 6. Effect of DMFP against glutamate-induced paw-licking test in mice. Each column represents 
the mean ± S.E.M. of 6 mice. The mice were pre-treated with vehicle (C), or DMFP (0.1, 0.5, 1 and  
5 mg/kg, i.p.) 30 min before i.pl. injection of 20 μL of glutamate (10 μmol/paw). The asterisks denote 
the significance level *** p < 0.001, when compared with control group (one-way ANOVA followed 
by Dunnett’s post-hoc test). Values in parentheses are percentage of inhibition. 
2.1.6. Involvement of Opioid Receptor 
The pre-administration of non-selective opioid receptor antagonist naloxone (5 mg/kg, i.p.) 
significantly antagonized the antinociceptive effect of morphine (5 mg/kg, i.p.) but was not able to 
antagonized the antinociceptive effect of DMFP (1 mg/kg, i.p.) in both the acetic acid-induced 
abdominal-writhing test (Figure 7) and the hot-plate test (Figure 8). Administration of naloxone per 
se did not affect both tests. 
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Figure 7. Effect of treatment with opioid antagonist, naloxone on the acetic acid-induced abdominal- 
writhing test in mice. Mice were pre-treated with naloxone (NALX, 5 mg/kg, i.p.) 15 min before the 
treatment with vehicle (C, 10 mL/kg, i.p), DMFP (0.1, 0.5, 1.0, 5.0 mg/kg, i.p.), or morphine (MOR,  
5 mg/kg, i.p.). Each column represents the mean ± S.E.M. of six mice. The asterisks denote significance 
levels *** p < 0.001, when compared with vehicle control group; ### p < 0.001, when compared with 
morphine (MOR)-treated group; ns denotes no significance level when compared with DMFP-treated 
group (one-way ANOVA followed by Dunnett’s post-hoc test.) 
Figure 7. Effec of tr a ment with opioid antagonist, naloxone on the acetic acid-induced
abdominal-writhing test in mic . Mice were pre-tre ted with naloxone (NALX, 5 mg/kg, i.p.) 15 min
b fore the treatm nt with vehicle (C, 10 mL/kg, i.p), DMFP (0.1, 0.5, 1.0, 5.0 mg/kg, i.p.), or morphine
(MOR, 5 mg/kg, i.p.). Each column represents the mean ± S.E.M. of six mice. Th as risks denote
significance levels *** p < 0.001, when compar d with vehicle control group; ### p < 0.001, when
compared with morphine (MOR)-treated group; ns denotes no significance level when compared with
DMFP-treated group (one-way ANOVA followed by Dunnett’s post-hoc test.)
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Figure 8. Effect of treatment with opioid antagonist, naloxone on the hot plate test in mice. Results 
are expressed in mean ± S.E.M. of response latency (s) of 6 mice. Statistical significance was denoted by 
one-way ANOVA followed by Dunnett’s post-hoc test. * p < 0.05; *** p < 0.001 compared with control 
group; ### p < 0.001, when compared with the group receiving appropriate drug/compound at the 
same dose without naloxone. Control ( ), morphine ( , 5.0 mg/kg, i.p.), morphine + naloxone 
( , 5.0 + 5.0 mg/kg, i.p.), DMFP ( , 5.0 mg/kg, i.p.) and DMFP + naloxone ( , 5.0 + 5.0 mg/kg, i.p.). 
2.2. Motor Performance Study 
2.2.1. Rota-Rod Test 
The administration of DMFP (5 mg/kg i.p.) did not cause any significant effect on the motor 
coordination of mice as assessed during the Rota-rod test when compared to the control group 
(Figure 9). In contrast, diazepam (4 mg/kg, i.p.) significantly reduced the time of permanence on the 
Rota-rod. 
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Figure 9. Effect of DMFP against on the Rota-rod test. Each column represents the mean ± S.E.M. in 
mice. Mice were pretreated with DMFP (5.0 mg/kg, i.p.) and diazepam (4.0 mg/kg, i.p.). Statistical analysis 
was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *** p < 0.001 compared with 
control (C) group. 
2.3. Toxicity Study 
2.3.1. Preliminary Acute Toxicity Study 
There were neither behavioral abnormalities nor mortality observed during 7 days period of 
observation in the treated mice. Gross morphological observation of stomachs and other organs of 
animals did not indicate any hemorrhagic lesions, ulcer or any other abnormalities. 
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Figure 4. Effect of DMFP on the hot plate test in mice. Results are expressed in mean ± S.E.M. f 
response latency (s) of 6 mice. Statistical significance was denoted by one-way ANOVA followed by 
Dunnett’s post-hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001 co pared  control gr up; tr l ), 
DMFP ( , 0.1; , 0.5;  1.0;  5.0 mg/kg, i.p.). 
2.1.4. Capsaicin-Induced Paw-Licking Test 
The administration of DMFP produced significant dose-dependent inhibition of the capsaicin- 
induced neurogenic nociception at all doses, as compared to control group with a highest activity of 
79.91% (p < 0.001) observed at the dose of 5.0 mg/kg (Figure 5). A imilar inhibitory effect was also 
observed for capsazepine, which achieved 69.44% (p < 0.001) inhibition of cap aicin-induced nociception. 
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Figure 5. Effect of DMFP against capsaicin-induced paw-licking test in mice. Each column represents 
the mean ± S.E.M. of 6 mice. The mice were pre-treated with vehicle (C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 
1.0 and 5 mg/kg, i.p.) or capsazepine (CAP, 0.17 mmol, i.p.) 30 min before intraplantar (i.pl.) injection of 
capsaicin (1.6 μg/paw, 20 μL). The asterisks denote the significance levels * p < 0.05, *** p < 0.001, 
when compared with control group (one-way ANOVA followed by Dunnett’s post-hoc test). Values 
in parentheses are percentage of inhibition. 
2.1.5. Glutamate-Induced Paw-Licking Test 
The results presented in Figure 6 show that the i.p. administration of DMFP at doses of 0.1, 0.5, 
1.0 and 5.0 mg/kg caused significant dose-dependent inhibition of glutamate-induced nociception, 
with 21.74% (p < 0.001), 40.67% (p < 0.001), 59.45% (p < 0.001) and 81.51% (p < 0.001) of inhibition as 
compared to control, respectively. 
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Figure 4. Effec  of DMFP on the hot plate t st in mice. Results are expressed in mean ± S.E.M. of 
response latency (s) of 6 mi e. Statistical significance was denoted by one-way ANOVA followed by 
D nnett’s post-hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001 compared with control group; Control ( ), 
DMFP , 0.1; , 0.5;  1.0;  5.0 mg/kg, i.p.). 
2.1.4. Capsaicin-Induced Paw-Licking Test 
The administration of DMFP produced significant dose-dependent inhibition of the capsaicin- 
induced neurogenic nociception at all doses, as compared to control group with a highest activity of 
79.91% (p < 0.001) observed at the dose of 5.0 mg/kg (Figure 5). A similar inhibitory effect was also 
observe for capsazepine, which chi v d 69.44% (p < 0.001) inhibition of capsaicin-induced nociception. 
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Figure 5. Effect of DMFP against capsaicin-induced paw-licking test in mice. Each column represents 
the mean ± S.E.M. of 6 mice. The mice were pre-treated with vehicle (C, 10 mL/kg, i.p.), DMFP (0.1, 0.5, 
1.0 and 5 mg/kg, i.p.) or capsazepine (CAP, 0.17 mmol, i.p.) 30 min before intraplantar (i.pl.) injection of 
capsaicin (1.6 μg/paw, 20 μL). The asterisks denote the significance levels * p < 0.05, *** p < 0.001, 
when compared with control group (one-way ANOVA followed by Dunnett’s post-hoc test). Values 
in parentheses are percentage of inhibition. 
2.1.5. Glutamate-Induced Paw-Licking Test 
The results presented in Figure 6 show that the i.p. administration of DMFP at doses of 0.1, 0.5, 
.  and 5.0 mg/kg caused significant dose-dependent inhibition of glutamate-induced nociception, 
with 21.74% (p < 0.001), 40.67% (p < 0.001), 59.45% (p < 0.001) and 81.51% (p < 0.001) of inhibition as 
compared to control, respectively. 
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2.3. Toxicity Study
Preliminary Acute Toxicity Study
There were neither behavioral abnormalities nor mortality observed during 7 days period of
observation in the treated mice. Gross morphological observation of stomachs and other organs of
animals did not indicate any hemorrhagic lesions, ulcer or any other abnormalities.
3. Discussion
The present study established the antinociceptive effects produced by the intraperitoneal
administration of a novel synthetic diarylpropanoid analogue, 3-(2,3-dimethoxyphenyl)-1-
(5-methylfuran-2-yl)prop-2-en-1-one (DMFP) in mouse models of induced nociception and explored
potential mechanisms of action. It was demonstrated for the first time that the administration of DMFP
produced significant peripheral and central antinociceptive activity when tested in different in vivo
chemicals and thermal experimental models of induced nociception, namely acetic acid-, formalin-,
capsaicin-, glutamate-induced nociceptive tests and the hot-plate test.
The acetic acid-induced abdominal-writhing test is considered as a conventional animal model
of pain and one of the most sensitive methods used for the screening of substances that have both
analgesic origin and/or anti-inflammatory effects [21,22]. It was suggested that the introduction of
acetic acid into the peritoneal cavity induces nociception by directly activating non-selective cationic
channels located in the primary afferent pathways or indirectly by promoting the release of various
endogenous algesic mediators such as prostaglandins, cytokines, bradykinin and others, as well as
increasing lipoxygenase (LOX) and cyclooxygenase (COX) production in peripheral tissues [23–26].
The release of these endogenous substances with subsequent stimulation and sensitization of the
peripheral primary afferent C-fibers neurons in the animal peritoneum produced a viscerosomatic
reflex leading to abdominal constrictions [23–25,27]. The findings of the present study indicate that
the administration (i.p.) of DMFP produced a significant dose-dependent reduction in the amount of
abdominal writhing induced by acetic acid as compared to the control group. This finding suggests
that the antinociceptive action of DMFP in the acetic acid-induced abdominal-writhing test could be
the result of inhibited release of endogenous algesic mediators or direct inhibitory activity at nerve
endings of the primary afferent neurons and/or inhibition of the transmission pathway entering the
dorsal horn.
Although the abdominal-writhing test has a very good sensitivity however it is non-specific in
nature, as in some cases its writhing response can be suppressed by muscle relaxants and other
types of drugs, which could lead to misinterpretation of the results. Furthermore, it does not
exactly discriminate the involvement of a central or peripheral mechanism [19,22]. For these reasons,
the possible inhibitory effect of DMFP was evaluated further in the formalin-induced paw-licking
and hot-plate tests, which are more specific tests for the investigation of peripherally and centrally
mediated antinociceptive activity [28,29].
The formalin-induced paw-licking test is a test model that produced two distinct phases of
nociceptive responses. The first phase (neurogenic) which reflects centrally mediated pain, is evoked
by direct formalin stimulation of the primary afferent C-fibers, result from the release of substance P,
serotonin, kinins and/CGRP. In contrast, the second phase (inflammatory), which reflects peripherally
mediated pain, is mainly due to either a subsequent inflammation reaction in the peripheral tissue
mediated by the release of various inflammatory mediators such as prostaglandins, COX and NO,
the effect of sensitizing dorsal horn neurons of the spinal cord or a combination of both [29,30].
The biphasic nature of the pain response in this test, which reflects different pathological processes,
can be used to elucidate the mechanism involved in analgesia [29]. In addition, it is well appreciated
that centrally acting drugs, such as opioids, inhibit both phases of pain, while peripherally acting
drugs such as acetylsalicylic acid and dexamethasone that inhibit COX activity actually inhibit only
the second phase [18,28,30]. The results of the present study show that the i.p. administration of
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DMFP significantly and dose-dependently attenuated the nociceptive response in both neurogenic and
inflammatory phases of the formalin-induced paw-licking test in mice. Correspondingly, both phases
of nociceptive response induced by formalin in the present study was also inhibited by the centrally
acting drug, morphine, while the peripherally acting drugs, ASA, only inhibited the second phase
of the test.
Similarly, the central antinociceptive effect of DMFP strongly supports the results obtained
in the hot-plate test, which is a preferential method to screen centrally acting analgesic drugs.
This effect is thought to demonstrate the involvement of central mechanisms (supraspinally) [22,31,32].
It was demonstrated that i.p. administration of DMFP exerts significant prolongation in the latency
response time to heat stimuli of the hot-plate test. Taking into account the inhibitory property of
the DMFP in the acetic acid-induced abdominal-writhing test, both phases of the formalin-induced
paw-licking test and the hot-plate test, it is strongly suggested that DMFP acting both centrally and
peripherally, which also implies that it possesses not only antinociceptive but also anti-inflammatory
activity. As far as central analgesic effect of DMFP is concerned, however, other studies by means of
intracerebroventricular and/or intrathecal routes of administration of DMFP are necessary to further
substantiate the involvement of central nervous system in the central analgesic effect of DMFP. Another
limitation of the present study is the lack of information on blood brain barrier (BBB) permeability
of DMFP. Several studies have reported the ability of chalcones and its analogues to cross the BBB
and have observed that it is possible for some chalcones to do so due to their lipophilic nature and
their specific interactions with the efflux transporters expressed in the epithelial cells that make up the
BBB [33,34] but for DMFP, its ability to cross the BBB is yet to determine. This information is crucial
in order to determine the potential direct drug-protein interaction of DMFP with different types of
receptors at the spinal or supraspinal levels cord, thus ascertain the exact mechanism of its central
analgesic effect.
Numerous reports have indicated the involvement of various endogenous systems in pain
control [25,35,36]. Therefore, in the present study we conducted preliminary experiments to explore
the involvement of opioids, TRVP1 and glutamate receptors in DMFP-induced antinociception.
The possible involvement of opioid receptors in the DMFP-induced antinociception was explored in a
separate group of mice using the acetic acid-induced abdominal-writhing test and the hot-plate test,
since the opioid receptors on peripheral terminals of primary afferent fibers can be the sites of the
intrinsic modulation of nociception [37]. In addition, it was reported that drugs with action on these
receptors may exerted analgesic effects without the presence of the central adverse effects caused by
opioids [38,39]. Numerous studies have shown that naloxone is capable of antagonizing the opioid
receptors in a non-selective manner [27,40]. Our findings showed that the inhibitory effect of DMFP in
both test models, in contrast to that of morphine, was not antagonized by pre-administration with
the non-selective opioid receptor antagonist, naloxone. The lacks of response to naloxone exclude
the involvement opioid receptors in antinociceptive of DMFP. Thus, these results imply that both the
peripheral and central mechanisms of DMFP-induced antinociception were neither mediated through
the activation of opioid receptors nor the modulation of the effect of endogenous opioid peptides.
Notably, DMFP significantly inhibited the nociceptive effect evoked by capsaicin and glutamate.
Capsaicin is a pungent ingredient of red chili peppers that acts directly to activate vanilloid receptor
type-1 (transient receptor potential cation channel V1 or TRPV-1) localized on nociceptive afferent
C-fibers, in the dorsal root ganglion of the spinal cord, trigeminal ganglia and CNS [36,41,42].
The stimulation of TRPV1 receptors promotes vascular leakage and vasodilatation, culminating
in the production and release of various neurotransmitters, such as glutamate and substance P,
NO and pro-inflammatory mediators from the peripheral and central terminals of primary afferent
neurons that contribute to nociceptive signal transmission and processing [41,42]. The results of the
present study show that DMFP attenuates the neurogenic pain perception caused by capsaicin in
a dose-dependent fashion. Also, it was observed that capsazepine, a selective capsaicin receptor
antagonist, significantly antagonized the nociception induced by capsaicin. Thus, these findings
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suggest that DMFP possibly exerts its analgesic effect via inhibition of the nociceptive transmission
initiated by TRPV1 receptors activation.
It is well appreciated that glutamate, a major excitatory amino acid neurotransmitter, participates
in the processes involved in nociceptive transmission, development and maintenance of the nociceptive
response through the activation of both ionotropic (iGluRs) and metabotropic glutamate receptors
(mGluRs), leading to the excitation and sensitization of peripheral, central spinal and/or supraspinal
nociceptors [43–45]. The iGluRs are nonselective ligand gated cation channels responsible for
fast synaptic transmission eliciting currents of Ca2+, Na+ or K+, whereas the mGluRs belong
to the large family of G-protein coupled receptors and are responsible for the neuromodulatory
activity of glutamate through the formation of second messengers, mainly inositol 1,4,5-triphosphate,
diacylglycerol and cyclic nucleotides. These receptors in different states and on different scales,
participate in induction, modulation or maintenance of pain [46,47]. Indeed, drugs capable of
inhibiting either iGluRs or/and mGluRs exhibit antinociceptive effects [45,48]. It was demonstrated
that i.pl. injection of glutamate into the mouse hind paw results in an increased influx of calcium
with the activation of neuronal NO synthase and NO formation [49]. The increase in the amount of
NO subsequently increases the release of pro-inflammatory mediators such as cytokines, reactive
oxygen species (ROS) and prostanoids and activates the formation of cyclic GMP, which enhances the
inflammatory reaction and producing nociceptive behaviors of rapid onset and short duration [49–51].
Consequently, inhibition of these receptors or decreased glutamate release at the level of peripheral,
spinal and/or supraspinal would lead to a decrease in pain perception. It was demonstrated in
the present study that the administration of DMFP produces significant dose-dependent inhibition
of the nociceptive response exerted by the i.pl. injection of glutamate in mice. Hence, the present
results strongly suggest that, at least in part, the antinociceptive activity induced by DMFP during
the glutamate test could be due to its interaction with the glutamatergic system and/or its ability
to inhibit NO production. However, this hypothesis should be confirmed by other experiments on
the mechanism of action of DMFP, which are currently in progress in our laboratory. This result also
substantiates the results observed in formalin- and capsaicin-induced paw-licking tests, as both studies
show that there is an increased level of glutamate as well as NO due to the stimulation of afferent
C-fibers following injection of formalin or capsaicin into the paw [22,30,42].
It is a matter of great concern in the investigation of analgesic action of compounds if
pharmacological administration of compounds causes other behavioral alterations, such as motor
incoordination and sedation, which might be misinterpreted as analgesic activity. Therefore in order to
avoid such misinterpretation, a behavioral evaluation was conducted to determine if DMFP-induced
antinociception were influenced by any disturbances on the central nervous system using the Rota-rod
test. It was observed that treatments with DMFP did not affect the motor activity of mice, thus exclude
possible false-positive results in analgesia or the influence of possible non-specific effects, such as
sedation or motor dysfunction. This result indicated that the behavioral responses observed in all
nociception induced experimental models in the current study were not due to behavioral alterations,
but was rather reflected a particular analgesic potential of DMFP.
Finally, to confirm the safety profiles of DMFP, our preliminary acute toxicological analysis was
performed in animals that received single oral dose treatment of DMFP. It was demonstrated after
7 days of observation, the animals even treated with the highest dose of DMFP up to 1 g/kg, did not
present any alteration in overall behavior and there was no occurrence of mortality. There were also no
changes in the gross macroscopic observations of the stomach and other vital organs, such the heart,
lung, liver, kidney and spleen. These results indicate that treatment with DMFP does not impair organ
function as assessed in this study, thus presenting good safety conditions and suggesting the efficacy
of the tested compound.
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4. Materials and Methods
4.1. General Information
All the reagents and solvents used were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA)
and were used without further purification. The melting points (mp.) were determined on a hot-stage
melting point apparatus, XSP-12 500X (Bibby Scientific Limited, Staffordshire, UK), and are uncorrected.
IR spectra were recorded on a Perkin–Elmer RXI Fourier transform (FT) IR spectrometer (Perkin
Elmer, Waltham, MA, USA) as KBr disks. Mass spectra were measured on a Finnigan Mat SSQ 710
spectrometer (Finnigan MAT, San Jose, CA, USA) with ionization induced by electron impact at 70 eV.
Then 1H-NMR spectra were recorded in CDCl3 using a Varian 500-MHz NMR spectrometer (Varian
Associates, Palo Alto, CA, USA). Column chromatography was performed on silica gel 60 Merck 9385
(230–400 mesh, ASTM). Thin layer chromatography (TLC) was performed on pre-coated silica plates
(Merck Kiesegel 60F254, 0.2 mm thickness) sheets.
4.2. Synthesis of 3-(2,3-Dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one (DMFP)
The synthetic diarylpropanoid analogue, DMPF (Figure 1) was chemically synthesized at the
Institute of Bioscience, Universiti Putra Malaysia. Briefly, to a mixture of 2-acetyl-5-methylfuran
(1.0 mmol) in ethanol (15 mL) was added with NaOH (1.5 mmol, 40%) and stirred for 10 minute in
cold water. Then, added substituted 2,5-dimethoxybenzaldehyde (1.0 mmol) and stirred the reaction
mixture at room temperature for 24 h. The progress of reaction was monitored by TLC and the reaction
mixture was poured over crushed ice and acidified with acetic acid. The crude products were dissolved
in distilled water and extracted with ethyl acetate. The yellow layer of EA was washed with water
and dried over sodium sulfate anhydrous. The compound was purified by column chromatography
using silica gel mesh size (100–200 mesh, Merck) and elution with petroleum ether and ethyl acetate.
Yield: 82%; yellow crystals; m.p. 132–134 ◦C. IR(CHCl3) υ: 2937 (C–H stretch), 1652 (C=O), 1600 (C=C),
1513 (C=C), 1269 (C–O aromatic), 1074, 1001 cm−1; 1H-NMR (500 MHz, CDCl3): δ 2.44 (s, 3H, CH3),
3.89 (s, 6H, 2 × OCH3), 6.22 (d, J = 3.0 Hz, 1H, H-4 furanyl), 6.97 (d, J = 8.0 Hz, 1H, H-4 phenyl), 7.11
(t, J = 8.0 Hz each, 1H, H-5 phenyl), 7.28 (d, J = 8.0 Hz, 1H, H-6 phenyl), 7.46 (d, J = 16 Hz, 1H, H-α),
7.24 (d, J = 3.0 Hz, 1H, H-3 furanyl), 8.15 (d, J = 16 Hz, 1H, H-β). EIMS m/z (rel. int.) calculated for
C16H16O4 (M+, %): 272 [M+].
4.3. Animals
Adult male ICR mice weighing 20–30 g were used. All mice were housed and maintained in the
Animal Unit, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia on a 12 h light/dark
cycle with standard commercialized rodent diet and water available ad libitum. Experimental groups
consisted of six randomly selected mice per group (n = 6), acclimatized for at least 1 h prior to
the experiment and used only once throughout the experiments. All animal care and experimental
protocols conducted in this study were approved by the Ethical Committee, Faculty of Medicine and
Health Sciences, Universiti Putra Malaysia (ACUC_UPM⁄ FPSK⁄ PADS ⁄BR-UUH⁄00330). The number
of animals and the intensities of noxious stimuli in the experimental protocols used were the minimum,
just the amounts necessary to demonstrate consistent effects of the drug treatments. The animals
used were euthanized by cervical dislocation immediately after completion of the experiment. In all
experiments, data were collected in a blinded, randomized and controlled design.
4.4. Drugs and Chemicals
The following drugs and chemicals were used: morphine hydrochloride, acetylsalicylic acid
(ASA), diazepam, Tween 20, absolute ethanol (100%), acetic acid, formalin, capsaicin, capsazepin,
glutamate and naloxone hydrochloride (Sigma-Aldrich Co.). DMPF and ASA were dissolved in a
vehicle containing absolute ethanol (5%), Tween 20 (5%) and normal saline (0.9% NaCl, 90%). The final
concentrations of ethanol and Tween 20 did not exceed 10% and did not cause any effect per se. All
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other drugs and chemicals used were dissolved in normal saline. Respective controls received only
vehicle. All drugs and DMPF solutions were prepared just before the experiments and administered
via the intraperitoneal route (i.p.) at a volume of 10 mL/kg. Doses and drugs administration schedules
were selected based our previous studies and on pilot experiments in our laboratory [9,13,18,19].
4.5. Antinociceptive Study
4.5.1. Acetic Acid-Induced Writhing Test
The acetic acid-induced abdominal-constriction test was performed as described previously with
slight modifications [19]. Experimental groups of mice were treated intraperitoneally (i.p.) with vehicle
(10 mL/kg), DMFP (0.1, 0.5, 1.0, 5.0 mg/kg) or ASA (100 mg/kg) 30 min before the administration of
acetic acid solution (0.6% v/v, 10 mL/kg, i.p.). Subsequently, the frequency of abdominal constriction
in the mice was cumulatively counted for each mouse over a period of 30 min. Antinociceptive activity
was expressed as a reduction in the number of abdominal constrictions between the control animals
and the mice that were pre-treated with the compounds.
4.5.2. Formalin-Induced Paw-Licking Test
The test was carried out as described previously [28], with minor modifications and licking of the
formalin injected paw behavior was selected over flinching, shaking, lifting or favoring behavior as
this was the established and optimized formalin-induced pain method used in our laboratory [9,19,35].
Briefly, 20 µL of 2.5% formalin solution (0.92% formaldehyde) in 0.9% saline solution was injected
intraplantar (i.pl.) into the right hind paw of the mouse with a 27-gauge needle fitted to a microsyringe.
The animal was then immediately placed into an observation perspex chamber and the amount of time
spent licking the injected paw was considered as indication of pain. Two distinct phases of intensive
licking and biting the paw activity were recorded using a chronometer during the first 5 min and
15–30 min, following formalin injection, and were measured as an early acute (neurogenic) phase and a
late tonic (inflammatory) phase of pain response, respectively. The mice were i.p. treated with vehicle
(10 mg/kg), DMFP (0.1, 0.5, 1.0, 5.0 mg/kg), ASA (100 mg/kg) or morphine (5 mg/kg), 30 min before
formalin injection.
4.5.3. Hot-Plate Test.
The hot-plate test was conducted to measure response latencies, according to a previously
described method with slight modifications [9]. In this experiment, the mice were treated with vehicle
(10 mL/kg, i.p.), DMFP (0.1, 0.5, 1.0, 5.0 mg/kg) or morphine (5 mg/kg, i.p.) and placed individually
on a hot plate (Model 7280, Ugo Basile, Varese, Italy) maintained at 52 ± 0.5 ◦C. All substances were
administered 30 min before the beginning of the experiment. The time elapsed between placement
of the animal on the heated surface of the hot plate and the occurrence of either licking of the hind
paws, shaking the paws or jumping off the surface was recorded as response latency. The response
latency was observed just before treatment (time 0) and 30, 60, 90, 120, 150 and 180 min after substance
administration. A latency of 20 s was defined as complete analgesia and used as a cut-off time to avoid
tissue injury to the animal’s paws. Mice in this experiment were selected 24 h before the experiment,
and only those showing response latency within the range of 5–8 s were used for the experiment.
4.5.4. Capsaicin-Induced Paw-Licking Test
The method performed was similar to that described previously with slight modification [42,52].
Mice received an intraplantar injection (i.pl.) of capsaicin (20 µL, 1.6 µg/paw) in the plantar surface of
the right hind paw. Immediately after the capsaicin injection, the animals were placed individually in an
observation perspex box and the amount of time the animal spent licking or biting the capsaicin-injected
paw was recorded for a period of 5 min and was considered as the nociceptive response. The animals
were pre-treated with vehicle (10 mL/kg, i.p.) or DMFP (0.1, 0.5, 1.0, 5.0 mg/kg, i.p.) 30 min before
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injection of capsaicin. In separate experiments animals received an intraplantar injection of capsazepine
(a capsaicin receptor antagonist, 0.17 mmol/kg, i.p.) 30 min before the capsaicin injection.
4.5.5. Glutamate-Induced Paw-Licking Test
The method used for glutamate-induced paw licking was similar to that described previously [49].
Mice were intraperitoneally pre-treated with vehicle (10 mL/kg, i.p.) or DMFP (0.1, 0.5, 1.0,
5.0 mg/kg, i.p.) 30 min before the i.pl. administration of glutamate (10 µmol/paw, 20 µL) in the ventral
surface of the right hindpaw. Immediately, animals were individually placed in a transparent perspex
box and the time that the animal spent licking or biting the glutamate-injected paw was recorded for a
period of 15 min and was considered as indication of nociception.
4.5.6. Involvement of Opioid Receptors
The possible participation of the opioid system in DMFP antinociceptive effect was evaluated
in separate groups of animals using the acetic acid-induced abdominal writhing and the hot-plate
tests. Mice were pre-treated with naloxone (5 mg/kg, i.p.) 15 min before the treatment with vehicle
(10 mL/kg, i.p), DMFP (0.1, 0.5, 1.0, 5.0 mg/kg, i.p.), ASA (100 mg/kg, i.p.) or morphine (5 mg/kg,
i.p.). 30 min after the treatments, the animals were subjected to the acetic acid-induced abdominal
writhing and hot-plate tests as described previously [9,18].
4.6. Motor Performance Study
Rota-Rod Test
The Rota-rod test was conducted to investigate whether DMFP has non-specific muscle relaxant
or sedative effects [53]. The Rota-rod apparatus (Model 7600, Ugo Basile) consisted of a bar with
diameter of 3 cm, and the rotating speed was set at speed of 20 rpm. The latency for the mice to fall
from the rotating rod were recorded. The animals were selected 24 h previously by eliminating those
which did not remain on the bar for two consecutive periods of 60s. The mice were given treatment
with vehicle (10 mg/mL, i.p.), DMFP (5 mg/kg, i.p.), or diazepam (4 mg/kg, i.p.) 30 min before being
tested. Motor performance was evaluated at 0, 30 and 60 min following the treatment. Each mouse
was subjected to two consecutive tests and results were averaged and expressed as the time (s) that the
animal remained on the rotated bar of the Rota-rod. The cut-off time was 60 s.
4.7. Toxicity Study
Preliminary Acute Toxicity Test
The acute toxicity test was carried out to evaluate a possible acute toxicity effect of DMFP as
previously described with some modifications [54]. Groups of mice received a single oral dose (p.o.)
of vehicle (10 mL/kg) or DMFP (1 g/kg) during 7 days period and their behavioral parameters
(i.e., convulsion, constipation, sedation, respiration, food and water intake) or mortality were observed.
On day 8 of observations, the animals were euthanized; organs were removed and opened to observe
any abnormalities (i.e., hyperemia and ulcer).
4.8. Statistical Analysis
Experimental groups consisted of six mice or rats. Data are presented as means ± S.E.M. The data
were analyzed by one-way analysis of variance (ANOVA) with Dunnett’s test for post-hoc comparisons
of different treatment groups with vehicle control. A value of p < 0.05 was considered statistically
significant in all tests. The effective dose 50 (ED50; dose producing a 50% reduction in the total
number of abdominal writhes) and 95% confidence interval (CI) values in the acetic acid-induced
abdominal-constriction test were determined by linear regression using GraphPad 5 (GraphPad
Software Inc., San Diego, CA, USA).
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5. Conclusions
In conclusion, we have demonstrated, through several in vivo experiments of induced nociception
in mice, that the administration of a novel synthetic diarylpropanoid analogue (DMFP), at a dose
that did not cause any toxic effects or interfere with motor coordination, produced prominent
peripheral and central antinociceptive effects. Based on the current results, DMFP’s peripheral
antinociceptive activity appears to be associated with the attenuated production and/or release
of NO and various pro-inflammatory mediators, while central antinociceptive activity seems to be
unrelated to the opioidergic system but could involve, at least in part, an interaction with the inhibition
of capsaicin-sensitive fibers and the glutamatergic system. The present observations on the numerous
targets involved contribute to a better understanding of the peripheral and central antinociceptive
mechanisms of action induced by DMFP, which also offer a promising option for further investigation
as an effective treatment for visceral and inflammatory pain.
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